Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue

Bristol Myers Squibb demonstrates steadier year-over-year revenue growth with consistent upward trends, while Pfizer shows higher absolute revenue but experienced recent fluctuations and contraction periods. BMY's revenue is projected to edge up 3% to $49.9 billion with net income rising over 40%, while PFE's revenue is expected to slump slightly to $62.2 billion despite net income gains. Based on revenue trends alone, Bristol Myers Squibb appears to be on a better trajectory, though both companies show positive comparable quarter-over-quarter growth.

10/22/2026, 5:25 PM • The Motley Fool

Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 Volatility

Bristol Myers Squibb has demonstrated more stable and consistent revenue growth over the past two years, leading in seven of eight quarters. Novo Nordisk experienced significant volatility, with a dramatic 32% revenue spike in Q1 2026 following its Wegovy weight-loss pill launch, but faced sequential declines in Q2 2026 due to pricing pressure and ordering patterns. While Novo Nordisk's GLP-1 portfolio drives investor interest, its heavy dependence on Ozempic and Wegovy (70% of sales) presents concentration risk compared to Bristol Myers Squibb's more diversified growth portfolio.

10/22/2026, 7:10 AM • The Motley Fool

Global Oral Drugs Market is Predicted to Surpass USD 1 Trillion Mark by 2034 | DelveInsight

The global oral drugs market is experiencing steady growth driven by increasing chronic disease prevalence and patient preference for convenient treatment options. The market is projected to grow from USD 1 trillion in 2025 to USD 1.6 trillion by 2034 at a ~6% CAGR. North America leads with 36% market share, while Asia-Pacific is expected to register the fastest growth. Key drivers include advancements in drug delivery technologies, expansion of oral therapies across oncology and other therapeutic areas, and rising pharmaceutical R&D investments.

10/21/2026, 1:00 PM • GlobeNewswire

Here's What I'm Planning With My Eli Lilly Position

An investment analyst discusses their strategy with Eli Lilly stock, highlighting the pharmaceutical industry's business growth and robust pipeline of new treatments. The article emphasizes the diversification benefits of pharmaceutical stocks due to their lower correlation with the broader economy.

10/20/2026, 11:26 PM • The Motley Fool

Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

Amgen and Bristol Myers Squibb represent different investment approaches in pharmaceuticals. Amgen demonstrates stronger revenue growth (~10% YoY) with higher profitability margins (21%) but trades at a premium valuation (P/E 26.4x). Bristol Myers Squibb offers significantly lower valuation (P/E 12.96x) and higher dividend yield (4.1%) with stronger free cash flow ($12.8B), though facing revenue headwinds and generic competition. For long-term dividend-focused investors, Bristol Myers Squibb is recommended despite near-term challenges.

10/20/2026, 5:45 PM • The Motley Fool

Have $1,000 to Invest? This Dirt Cheap Pharma Stock Pays You 4.2% to Wait.

Bristol Myers Squibb offers a 4.2% dividend yield and trades at a significant valuation discount (9.5x forward earnings) compared to peers (15-20x). While the dividend alone is modest, the main investment thesis centers on the company's turnaround potential. If its growth portfolio successfully offsets legacy drug patent expirations, the stock could experience substantial rerating upside. The company's sub-40% payout ratio suggests dividend safety in the near term.

10/20/2026, 7:16 AM • The Motley Fool

Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?

BioNTech faces mounting clinical setbacks in its cancer vaccine pipeline, including a halted Phase 2 trial for autogene cevumeran and BNT113's failure to meet a primary endpoint in head and neck cancer trials. With COVID-19 vaccine revenues declining sharply (down 60% YoY) and the company unprofitable, investors must weigh the deep pipeline potential against significant uncertainty. The stock is recommended only for risk-tolerant investors.

10/18/2026, 2:32 PM • The Motley Fool

Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline

BioNTech has 16.6 billion euros in cash and is advancing 14 pivotal oncology trials, positioning itself to transition from a COVID-19 vaccine maker to a major cancer treatment company. With a diversified pipeline including promising candidates like pumitamig and a $1 billion share repurchase program, the company has financial flexibility to fund development. However, risks include trial failures, declining COVID-19 revenue, and regulatory delays.

10/17/2026, 12:23 PM • The Motley Fool

Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

The article compares Bristol-Myers Squibb and Johnson & Johnson as healthcare investment options. BMY trades at a cheaper valuation (9.3x forward P/E vs JNJ's 21x) with a higher dividend yield of 4.16%, but faces patent cliffs and pricing pressures. JNJ offers greater revenue scale ($94.2B vs $48.2B), diversified business segments, and a 64-year dividend growth streak, making it the recommended choice for 2026 despite its premium valuation.

10/16/2026, 8:50 PM • The Motley Fool

BlackLine Honors Global Enterprise Leaders Transforming Financial Operations

BlackLine announced its 2026 Modern Accounting Awards, honoring six enterprise leaders—Booking Holdings, Bristol Myers Squibb, James Hardie, LAZ Parking, Payoneer, and US Foods—for redefining financial operations through unified data architectures, intelligent automation, and agentic workflows. These organizations have eliminated tens of thousands of manual close hours and established continuous, audit-ready financial operations.

10/13/2026, 9:00 AM • GlobeNewswire

Stocks Are Expensive and Investors Are Getting Scared. Warren Buffett's 13-Word Rule Has Specific Advice for Both Conditions.

The market currently exhibits conflicting signals with investors experiencing fear (CNN Fear & Greed Index at 38) while valuation metrics like the Buffett Indicator (237%) and Shiller CAPE ratio suggest greed. Buffett's contrarian investing rule advises being fearful of overvalued growth stocks while seeking greedy opportunities in undervalued sectors like energy and healthcare. Success requires balancing both extremes rather than acting on a single indicator.

10/11/2026, 4:26 AM • The Motley Fool

How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends?

To generate $1,000 monthly in dividend income ($12,000 annually), investors should diversify across five pharmaceutical stocks rather than concentrating in high-yield Pfizer alone. Investing $70,000 each in Pfizer, Johnson & Johnson, AbbVie, Bristol Myers Squibb, and Amgen creates a balanced portfolio that reduces risk from patent expirations and potential dividend cuts while maintaining steady income.

10/10/2026, 10:15 PM • The Motley Fool

Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

The article compares Bristol Myers Squibb and Pfizer as healthcare investment options for 2026. Both face patent cliffs and regulatory pressures, but Pfizer is recommended as the better choice due to its clearer post-patent roadmap, growing non-COVID products, obesity drug positioning, and committed dividend protection. Bristol Myers Squibb shows near-term momentum improvements but faces longer-term revenue uncertainty from patent losses and drug pricing reforms.

10/08/2026, 8:43 PM • The Motley Fool

Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors

Aardvark Therapeutics appointed David Zhang, Ph.D., MBA, as an independent board director, bringing over 25 years of clinical development and regulatory expertise from companies including MyoKardia, Genentech/Roche, Alumis, and Abivax. Zhang will support Aardvark's regulatory strategy for ARD-101, its lead candidate for Prader-Willi Syndrome treatment, at a critical juncture following an FDA clinical hold.

10/08/2026, 8:00 AM • GlobeNewswire

2 High-Yield Stocks to Buy in October (Hint: Bristol Myers Squibb Is One)

The article recommends two high-yield stocks for October: Bristol Myers Squibb (BMY) offering a 4.2% dividend yield despite facing near-term patent expiration challenges, and Realty Income (O) with a 6% yield and 31-year dividend increase streak, though facing headwinds from rising interest rates. Both stocks are trading at attractive valuations due to short-term concerns, presenting opportunities for long-term income-focused investors.

10/07/2026, 7:15 PM • The Motley Fool